Key result
New oral anticoagulants, including direct thrombin and factor Xa inhibitors, have emerged as attractive alternatives to warfarin for stroke prevention in atrial fibrillation.
Why the study?
Do oral direct thrombin inhibitors and direct factor Xa inhibitors prevent stroke in patients with atrial fibrillation compared to warfarin?
Do oral direct thrombin inhibitors and direct factor Xa inhibitors prevent stroke in patients with atrial fibrillation compared to warfarin?
Answers are grounded in this paper and cite their sources.
New oral anticoagulants offer important advantages over warfarin for stroke prevention in atrial fibrillation, but real-world long-term data is still needed.
Warfarin has long been the 'gold standard' of oral anticoagulation for stroke prevention in atrial fibrillation (AF). Recently, the oral direct thrombin inhibitors and direct factor Xa inhibitors have emerged as attractive alternatives to warfarin and have already changed the landscape of stroke prevention in AF. The new anticoagulants have important advantages over warfarin. Despite their impressive performance in clinical trials, their long-term efficacy and safety still require evaluation in 'real-world' clinical practice. In this review, the emerging role of the new oral anticoagulants for stroke prevention in patients with AF is discussed.
No takes yet. Share an insight, caveat, or question.
Potpara et al. (2012) conducted a review in atrial fibrillation. New oral anticoagulants (direct thrombin inhibitors and direct factor Xa inhibitors) vs. Warfarin was evaluated on Stroke prevention. New oral anticoagulants, including direct thrombin and factor Xa inhibitors, have emerged as attractive alternatives to warfarin for stroke prevention in atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: